Bristol Myers Squibb has confirmed that Houston, Texas, will be the site of a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3bn investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.
The selection of Houston marks a significant milestone in BMS’ $40bn commitment to invest in the United States over five years across research and development, technology and domestic manufacturing.
The modular design of the Houston campus allows BMS to add and reconfigure manufacturing capacity as needed, reflecting the company’s current and future pipeline. Its multi-modal capabilities allow for the manufacture of multiple types of medicines – such as small molecules, biologics and antibody-drug conjugates – across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch. This flexibility ensures the campus can evolve to meet patient needs well into the future.
Christopher Boerner, Board Chair and CEO of Bristol Myers Squibb, commented: “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb, said: “This facility is designed to deliver the speed, quality and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities.”